```markdown
---
application_number: NDA 209191
sponsor: Hospira, Inc.
contact_person: Pamela Cabrera, PharmD
contact_title: Senior Associate, Global Regulatory Affairs
contact_address: 275 N Field Drive, Building H2-2, Department 0389, Lake Forest, IL 60045
product_name: Bortezomib for Injection
strength: 2.5 mg/vial
regulatory_project_manager: Kris Kolibab
regulatory_contact_phone: (240) 402-0277
review_offices:
  - name: Division of Hematology Products
    director: Ann T. Farrell, MD
  - name: Division of Hematology Products
    supervisory_director: Albert Deisseroth, MD, PhD
communication_dates:
  - December 22, 2017
  - October 18, 2017
approval_status:
  - type: Complete Response
    deficiencies: 
      - Product Quality
      - Prescribing Information
      - Carton and Container Labeling
      - Safety Update
      - Facility Inspections
      - Miscellaneous Regulatory Actions
  - type: Tentative Approval
    caveats:
      - Patent protection delays final approval
      - Paragraph IV litigation ongoing
---

## Critical Data

- **Application Number**: NDA 209191  
- **Sponsor**: Hospira, Inc.  
- **Regulatory Contact**: Pamela Cabrera, PharmD  
- **Product**: Bortezomib for Injection, 2.5 mg/vial  
- **Regulatory Project Manager**: Kris Kolibab, (240) 402-0277  
- **Review Divisions**:
  - Division of Hematology Products, Director: Ann T. Farrell, MD  
  - Supervisory Associate Division Director: Albert Deisseroth, MD, PhD  
- **Communication Types**: Complete Response, Tentative Approval  
- **Key Issues Identified**:
  - Product Quality: Elemental impurity testing, compliance with ICH Q3D and USP <232/233>  
  - Prescribing Information: SRPI compliance, labeling not yet adequate  
  - Carton/Container Labeling: Drafts required consistent with prior submissions  
  - Safety: Required updates per 21 CFR 314.50(d)(5)(vi)(b)  
  - Facility Inspections: Deficiencies to be resolved  
  - Intellectual Property: Patent 6,713,446, litigation in progress  
- **Pediatric Requirement**: Assessment required unless waived/deferred  
- **Marketing Status**: Not approved for commercial marketing pending final approval  

---

# CENTER FOR DRUG EVALUATION AND RESEARCH  
## Application Number: NDA 209191  

---

## COMPLETE RESPONSE  
**To:** Hospira, Inc.  
**Attention:** Pamela Cabrera, PharmD  
Senior Associate, Global Regulatory Affairs  
275 N Field Drive  
Building H2-2, Department 0389  
Lake Forest, IL 60045  

**Product:** Bortezomib for Injection, 2.5 mg/vial

### Product Quality  
- Establish a validated test method for elemental impurities as part of the drug product specification consistent with ICH Q3D and USP <232/233>.  
- Update the drug product specifications accordingly with controls for elemental impurities, if necessary.

### Prescribing Information  
- Comment is reserved on the proposed labeling until the application is otherwise adequate.  
- Review the PLR Requirements for Prescribing Information and Pregnancy and Lactation Labeling Final Rule websites, including guidance documents and Selected Requirements for Prescribing Information (SRPI).  
- If labeling is revised, use the SRPI checklist to ensure format compliance.  
- Submit updated labeling content in SPL format:  
  [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm)

### Carton and Container Labeling  
- Submit draft carton and container labeling identical to those submitted on December 22, 2017.

### Safety Update  
Include a safety update per 21 CFR 314.50(d)(5)(vi)(b), covering all nonclinical and clinical studies/trials:

1. Describe in detail any significant changes or findings in the safety profile.  
2. Incorporate new safety data:
   - Present new safety data for the proposed indication using the original format.
   - Combine new safety data with original tabulations.
   - Include tables comparing original and new adverse event frequencies.
   - Provide separate tables for other indications from clinical trials.
3. Retabulate reasons for premature trial discontinuation incorporating dropouts from newly completed trials.  
4. Provide case report forms and narrative summaries for:
   - Patients who died during a clinical trial  
   - Patients who discontinued due to adverse events  
   - Serious adverse events  
5. Describe any significant change in incidence of common but less serious adverse events.  
6. Provide updated exposure information (e.g., number of subjects, person time).  
7. Summarize worldwide experience and updated estimate of use in other countries.  
8. Provide English translations of any current approved foreign labeling not previously submitted.

### Other  
- You must act within one year of this letter under 21 CFR 314.110.  
- Lack of response may be considered a request to withdraw the application (21 CFR 314.65).  
- A resubmission must fully address all deficiencies and be clearly labeled "RESUBMISSION" in large, bold font.  
- You may request a meeting or teleconference following guidance:  
  [FDA Formal Meetings Guidance (March 2015)](http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm437431.pdf)  
- The drug product may not be marketed until written notification of approval is received.  

**Contact:** Kris Kolibab, Senior Regulatory Project Manager, (240) 402-0277  

**Signed Electronically:**  
Ann T. Farrell, MD  
Director, Division of Hematology Products  
Office of Hematology and Oncology Products  
Center for Drug Evaluation and Research

---

## COMPLETE RESPONSE  
**To:** Hospira, Inc.  
**Attention:** Pamela Cabrera, PharmD  
275 North Field Drive, Dept. 0389  
Lake Forest, IL 60045  

**Product:** Bortezomib for Injection, 2.5 mg/vial

### Facility Inspections  
- FDA field investigator conveyed manufacturing facility deficiencies.  
- Satisfactory resolution is required prior to approval.

### Prescribing Information  
- See previous complete response prescribing information instructions.

### Carton and Container Labeling  
- Submit draft packaging identical to those submitted on October 18, 2017.

### Safety Update  
- See previous complete response safety update requirements.

### Other  
- See previous complete response miscellaneous regulatory instructions.

**Contact:** Kris Kolibab, Senior Regulatory Project Manager, (240) 402-0277  

**Signed Electronically:**  
Ann T. Farrell, MD  
Director, Division of Hematology Products  
Office of Hematology and Oncology Products  
Center for Drug Evaluation and Research

---

## TENTATIVE APPROVAL  
**To:** Hospira, Inc.  
**Attention:** Pamela Cabrera, PharmD  
275 N Field Drive, Dept. 0389  
Lake Forest, IL 60045  

**Product:** Bortezomib for Injection, 2.5 mg/vial  
**Indication:** Treatment of patients with multiple myeloma

### Approval Status  
- Tentative approval under 21 CFR 314.105 based on available information and current cGMP status.  
- Final approval delayed due to patent protection.

### Intellectual Property  
- Paragraph IV certification submitted for patent 6,713,446.  
- Patent litigation initiated: United States District Court, District of Delaware (Case 1:16-cv-00998-UNA).  
- Final approval cannot be granted until:
  1. a. Expiration of the 30-month window after notification  
     b. Court judgment of invalidity or non-infringement  
     c. Patent expiration  
  2. No new disqualifying information arises  

- To obtain final approval:
  - Submit amendment 2 or 6 months before the expected final approval date.  
  - Clearly mark submission: **"REQUEST FOR FINAL APPROVAL"**  
  - Include legal documentation and relevant updates (e.g., safety, labeling, CMC, REMS)

- The product cannot be legally marketed until final approval is granted.

### Proprietary Name  
- If used, the name must comply with 21 CFR 201.10 and 201.15 regulations.  
- Submit proposed proprietary name per:  
  [FDA Proprietary Name Guidance](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075068.pdf)

### Required Pediatric Assessments (PREA)  
- NDA must assess the product in pediatric populations unless waived, deferred, or inapplicable.  

**Contact:** Kris Kolibab, Senior Regulatory Project Manager, (240) 402-0277  

**Signed Electronically:**  
Albert Deisseroth, MD, PhD  
Supervisory Associate Division Director  
Division of Hematology Products  
Office of Hematology and Oncology Products  
Center for Drug Evaluation and Research
```